Acrux Signs 10-Year Licensing Deal For Dapsone Gel in Saudi Arabia

MT Newswires Live

Jul 31, 2025

Acrux (ASX:ACR) has signed a 10-year agreement with Servacure Trading to market and distribute its food and drug administration-approved Dapsone 5% Gel in Saudi Arabia, according to a Thursday filing with the Australian bourse.

The product, launched in the US in April 2024 for treating acne vulgaris and available in 60g and 90g packs, will have its regulatory approval and manufacturing managed by Servacure under the agreement, the filing said.

The company will earn a fixed fee per unit shipped monthly, with options to renew the contract after the initial term, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2555052990"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555052990\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555052990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 14:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555052990","market":"us","top_or_hot":-1,"title":"Acrux Signs 10-Year Licensing Deal For Dapsone Gel in Saudi Arabia","media":"MT Newswires Live","content":"<html><body><p> Acrux (ASX:ACR) has signed a 10-year agreement with Servacure Trading to market and distribute its food and drug administration-approved Dapsone 5% Gel in Saudi Arabia, according to a Thursday filing with the Australian bourse.</p><p>The product, launched in the US in April 2024 for treating acne vulgaris and available in 60g and 90g packs, will have its regulatory approval and manufacturing managed by Servacure under the agreement, the filing said.</p><p>The company will earn a fixed fee per unit shipped monthly, with options to renew the contract after the initial term, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acrux Signs 10-Year Licensing Deal For Dapsone Gel in Saudi Arabia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcrux Signs 10-Year Licensing Deal For Dapsone Gel in Saudi Arabia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-31 14:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Acrux (ASX:ACR) has signed a 10-year agreement with Servacure Trading to market and distribute its food and drug administration-approved Dapsone 5% Gel in Saudi Arabia, according to a Thursday filing with the Australian bourse.</p><p>The product, launched in the US in April 2024 for treating acne vulgaris and available in 60g and 90g packs, will have its regulatory approval and manufacturing managed by Servacure under the agreement, the filing said.</p><p>The company will earn a fixed fee per unit shipped monthly, with options to renew the contract after the initial term, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2555052990","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555052990","pubTimestamp":1753942573,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Acrux  has signed a 10-year agreement with Servacure Trading to market and distribute its food and drug administration-approved Dapsone 5% Gel in Saudi Arabia, according to a Thursday filing with the Australian bourse.The product, launched in the US in April 2024 for treating acne vulgaris and available in 60g and 90g packs, will have its regulatory approval and manufacturing managed by Servacure under the agreement, the filing said.The company will earn a fixed fee per unit shipped monthly, with options to renew the contract after the initial term, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","ACR.AU":"ACRUX LTD","BK7096":"制药"},"translate_title":"Acrux在沙特阿拉伯签署为期10年的氨苯砜凝胶许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACR.AU":0.9},"content_text":"Acrux (ASX:ACR) has signed a 10-year agreement with Servacure Trading to market and distribute its food and drug administration-approved Dapsone 5% Gel in Saudi Arabia, according to a Thursday filing with the Australian bourse.The product, launched in the US in April 2024 for treating acne vulgaris and available in 60g and 90g packs, will have its regulatory approval and manufacturing managed by Servacure under the agreement, the filing said.The company will earn a fixed fee per unit shipped monthly, with options to renew the contract after the initial term, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}